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Human CD81 (hCD81) protein has been recombinantly produced in the methylotrophic yeast Pichia pastoris. The puriﬁed protein,
produced at a yield of 1.75 mg/L of culture, was shown to interact with Hepatitis C virus E2 glycoprotein. Immunoﬂuorescent and ﬂow
cytometric staining of P. pastoris protoplasts with monoclonal antibodies speciﬁc for the second extracellular loop (EC2) of hCD81con-
ﬁrmed the antigenicity of the recombinant molecule. Full-length hCD81 was solubilized with an array of detergents and subsequently
characterized using circular dichroism (CD) and analytical ultracentrifugation. These biophysical techniques conﬁrmed that the protein
solution comprises a homogenous species possessing a highly-deﬁned a-helical secondary structure. The predicted a-helical content of the
protein from CD analysis (77.1%) ﬁts remarkably well with what would be expected (75.2%) from knowledge of the protein sequence
together with the data from the crystal structure of the second extracellular loop. This study represents the ﬁrst biophysical character-
ization of a full-length recombinant tetraspanin, and opens the way for structure–activity analyses of this ubiquitous family of transmem-
brane proteins.
 2007 Elsevier Inc.
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Open access under CC BY license.CD81 is a four transmembrane domain membrane pro-
tein of the tetraspanin (TSP) superfamily [1]. To date 34
family members have been identiﬁed in mammals, of which
33 are present in humans. Common to all tetraspanins are
the four transmembrane (TM) spanning regions containing
several conserved polar residues and, in most cases, rela-
tively short cytoplasmic amino- and carboxy-terminal tails
[2]. These TM domains are linked via a short extracellular
loop 1 (EC1)2 and a larger extracellular loop 2 (EC2) con-
taining the highly conserved Cys-Cys-Gly motif unique to1046-5928 2007 Elsevier Inc.
doi:10.1016/j.pep.2007.10.013
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Open access under CC BY license.tetraspanins. Between 4 and 8 Cys residues can be found
in the EC2 loop. These residues form several disulﬁde
bridges [3], which are critical for correct folding of the
EC2 domain and subsequent interaction with ligands and
partner proteins [2,4]. In human CD81 (hCD81) there are
four such residues (Fig. 1).
The exact biochemical function of tetraspanins is not
well understood, but they are implicated in a variety of
key cellular processes including oocyte fertilization, tissue
diﬀerentiation, cell adhesion, tumor growth and cell metas-
tasis [4]. Emerging evidence also reveals tetraspanin associ-
ation with signaling lipids, cytoplasmic proteins [4] and
adhesion receptors of the integrin family to facilitate the
assembly of tetraspanin-enriched microdomains also
known as the ‘tetraspanin web’. In the case of hCD81, it
has a role in B- and T-cell activation [4,5] and interacts
Fig. 1. Schematic representation of the hCD81 protein produced in this
study. The mutated palmitoylation sites (Cys to Ala) are highlighted as
white circles in the sequence. The His6 tag is indicated as a rectangle in the
carboxy-terminal tail. The two extracellular loops are marked as EC1 and
EC2. EC2 contains the conserved Cys-Cys-Gly (CCG) motif associated
with the tetraspanin family. The published crystal structure of soluble EC2
indicates the importance of this motif in forming the disulﬁde bridges
represented in the ﬁgure. The membrane is represented in grey.
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proteins [6]. Recent research has also revealed that hepati-
tis C virus (HCV) E2 envelope glycoprotein binds to the
EC2 domain of hCD81 [7] and that hCD81 is a critical
co-receptor deﬁning HCV entry [8–10]. hCD81 is further
implicated in Plasmodium falciparum infectivity, leading
to malaria [11].
Despite their intriguing roles in so many normal and dis-
ease states, tetraspanin structure–activity relationships are
poorly understood. To date the only crystal structure of
any tetraspanin is that of the soluble EC2 domain of
hCD81 [3], which reveals a mushroom shaped loop con-
ﬁrming the presence of the highly conserved Cys-Cys-Gly
motif and two intact disulﬁde bridges. However, elucida-
tion of the full-length hCD81 structure is necessary in order
to facilitate an understanding of in vivo binding and the
role of the TM domains in speciﬁc interactions with biolog-
ically-relevant ligands. As a consequence, structural infor-
mation of a full-length tetraspanin would provide
valuable insight into possible mechanisms of action. More-
over, since about 2% of the world’s population is chroni-
cally infected with HCV, resulting in hepatitis, cirrhosis,
liver failure and hepatocellular carcinoma, hCD81 is a clin-
ically-important anti-viral drug target.
Tetraspanins (like other human membrane proteins)
have been diﬃcult to overproduce in a puriﬁed form for
detailed biophysical analyses. In this study we report the
production of hCD81 in Pichia pastoris as well as its opti-
mized solubilization and puriﬁcation which yields milli-
gram quantities of correctly-folded, pure protein for
biophysical characterization. Structural integrity was fol-
lowed throughout production via binding of conformation-
ally-speciﬁc anti-hCD81 monoclonal antibodies [12] to
both membrane-integrated and detergent-solubilized
hCD81. Function was conﬁrmed by binding to a known
ligand, HCV E2 glycoprotein [7]. Using circular dichroism(CD) and analytical ultracentrifugation (AUC), the puri-
ﬁed protein was shown to be recovered as a highly-pure,
homogeneous species that is predominantly a-helical in
nature. This study represents the ﬁrst biophysical charac-
terization of a recombinant tetraspanin, and paves the
way for detailed structure–function analyses of tetraspa-
nins using NMR and X-ray crystallography.
Materials and methods
Plasmid construction
DNA encoding hCD81 (GeneID: 975) was ampliﬁed
using a 3-step, site-speciﬁc mutagenesis PCR approach to
remove all palmitoylation sites (Cys to Ala) in the central
segment of hCD81 as indicated in the protein sequence
(Fig. 1). The ﬁrst hCD81 ampliﬁcation product incorpo-
rated an EcoRI site (underlined) followed by a Kozak con-
sensus sequence (bold) and removed the palmitoylation
sites in the native sequence through the use of the forward
primer 1, 5 0-GGTCGGAATTCAAAATGTCTGGAGT
GGAGGGCGCCACCAAGGCCATCAAGTACCTG-3 0
and reverse primer 1, 5 0-GGATTCCTGGATGGCCCCG
TAGGCGCCCAGGAAGCCAACGAACA T-3 0. For-
ward primer 2, 5 0-TACGGGGCCATCCAGGAATC
CCAGGCTCTGCTGGGGGACGTT-3 0 (overlapping
reverse primer 1) in combination with reverse primer 2,
5 0-GCACCCTCGAGTCAATGATGATGATGATGATGG
CCGCCGCCGTACACGGAGCTGTTCCGGATGCCT
GCGGCCAGCACCAT-3 0 was used to remove all remain-
ing palmitoylation sites and introduce a carboxy-terminal
His6 tag (bold), a stop codon and a XhoI site (underlined).
The full-length, mutant product was ampliﬁed using for-
ward primer 1 and reverse primer 2 and cloned into the
P. pastoris vector pPICZB using the EcoRI and XhoI sites.
Yeast strains, growth conditions and expression screening
The hCD81 expression plasmid was linearized with the
restriction endonuclease PmeI, puriﬁed, concentrated to
0.5–1 lg DNA/lL, and used to transform P. pastoris
wild-type strains X-33 and GS115 (Invitrogen) by electro-
poration, as described by the manufacturer (Invitrogen)
using P. pastoris competent cells produced as described
by Cereghino and colleagues [13]. Ten transformants were
cultured in BMGY medium (1% yeast extract, 2% peptone,
1.34% yeast nitrogen base without amino acids, 0.00004%
biotin, 1% glycerol, 0.1 M phosphate buﬀer, pH 6) at
30 C and 230 rpm overnight to yield an OD600 of 2–10.
Production screening for hCD81 was induced in 3 mL
BMMY medium (BMGY containing 1% methanol instead
of 1% glycerol) at 30 C and an initial OD600 of 1 in 24-well
uniplates (Whatman). Protein production was maintained
by addition of methanol (to a ﬁnal concentration of 1%
(v/v)) 24 h and 48 h post-induction. Samples were collected
by centrifugation at 6, 24 and 54 h post-induction to ana-
lyze production yields and determine the optimal harvest
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frozen in liquid N2, and stored at 80 C. For reducing
SDS–PAGE, whole cell lysates from each time point were
prepared by heating these cell pellets at 98 C for 10 min
in sample buﬀer (50% distilled water, 12.5% 0.5 M Tris–
HCl, pH 6.8, 10% glycerol, 2% SDS, 5% b-mercap-
toethanol and 0.001% (w/v) bromophenol blue). They were
then loaded onto a 12% Tris–HCl gel, transferred to a
nitrocellulose membrane (Hybond ECL, GE Healthcare),
and analyzed by immunoblotting with either a primary
monoclonal anti-His6 antibody (Clontech) or a primary
anti-hCD81 monoclonal antibody together with an anti-
mouse IgG HRP-conjugated secondary antibody (Sigma).
For non-reducing SDS–PAGE, b-mercaptoethanol was
omitted from the sample buﬀer. The samples in Figs. 2
and 4 are loaded in SDS–PAGE loading buﬀer without
the addition of b-mercaptoethanol. This means that the
proteins have been partially denatured with SDS, but not
reduced. In Fig. 5, the SDS–PAGE loading buﬀer contains
b-mercaptoethanol, meaning that the proteins are fully
denatured. The protein signal was detected by EZ-ECL
chemiluminescence (Geneﬂow) and analyzed with a UVIp-
rochemi imaging system (UVItec). The highest yielding P.
pastoris transformant (subsequently referred to as X33-
hCD81) identiﬁed by this analysis was cultured in 10 mL
of BMGY medium overnight at 30 C at 230 rpm. This cul-
ture was subsequently inoculated to OD600 = 1 into a ster-
ile 250 mL shake ﬂask containing 50 mL of BMMY. The
culture was supplemented with methanol (ﬁnal concentra-
tion of 1% (v/v)) 24 and 48 h post-induction. After 54 h,
the culture was centrifuged and the pellet was retained
for protein analysis and puriﬁcation. For large-scale pro-
tein production and puriﬁcation, P. pastoris wild-type
strain X-33 producing recombinant hCD81 was grown in
2 L of BMMY, inoculated to a ﬁnal OD600 = 1 in a 5 L
shake ﬂask for 54 h with the addition of methanol (ﬁnal
concentration of 1% (v/v)) 24 h and 48 h post-induction.
Membrane preparation
All work was carried out at 0–4 C. Twenty grams of
X33-hCD81 cells were suspended in 40 mL ice-cold break-
ing buﬀer (50 mM sodium–phosphate buﬀer, pH 7.4,
100 mM NaCl, 5% glycerol, 2 mM PMSF) and poured into
an Avestin-C3 cell disrupter. Yeast cells were broken by
three passages through the chilled cell, and breaking eﬃ-
ciency was >90% when inspected with a light microscope.
Unbroken cells and cell debris were removed from the
membrane suspension by low-speed centrifugation
(10,000g, 30 min, 4 C). Membranes were then collected
using an ultracentrifuge (100,000g, 90 min, 4 C), sus-
pended in solubilization buﬀer (20 mM Hepes, pH 7.4,
100 mM NaCl, 10% glycerol, 1 mM PMSF). The protein
content of the membrane fraction was quantiﬁed using
the Bio-Rad Protein Assay Kit [14]. Standard curves were
prepared each time the assay was performed as described
by the manufacturer, using aqueous solutions of bovineserum albumin (Fraction V) as a standard. Membranes
were snap-frozen in liquid nitrogen and stored at 80 C.
Immunoblots on membrane preparations were performed
as described above.
Solubilization and puriﬁcation
A detergent screen was performed on hCD81-containing
membranes (with a total protein content of 0.6 mg protein)
in 100 lL solubilization buﬀer (20 mM NaPO4, pH 7.4,
250 mM NaCl, 10% glycerol, 100 lM 4-(2-aminoethyl)ben-
zenesulphonyl ﬂuoride (Roche), AEBSF) using the follow-
ing panel of detergents at 2% w/v on membrane
suspensions: n-dodecyl-b-D-maltopyranoside (DDM), n-
dodecylphosphocholine (DPC), cyclofos-4 (CYFOS-4), n-
octyl-b-D-glucopyranoside (b-OG), foscholineiso9
(FCI09), lauryldimethylamine oxide (LDAO), pentaethyl-
eneglycol-n-octylether (C8E5), n-dodecylphosphocholine–
cholesterolhemisuccinate (DPC/CHS) and docosaethylene-
glycol–monohexadecylether (Brij 58; all purchased from
Anatrace Inc). Samples were incubated for 1 h at room
temperature with mild agitation. Non-solubilized material
was removed by centrifugation at 18,000g for 2 h at 4 C.
The solubilized (supernatant) and non-solubilized (mem-
brane pellet) material were analyzed by immunoblot anal-
ysis for solubilization eﬃciency using a primary anti-
hCD81 monoclonal antibody and an anti-mouse IgG
HRP-conjugated secondary antibody (Sigma). For scale-
up, 10 mL of membranes (300 mg protein) were added to
10 mL of solubilization buﬀer containing detergent to a
ﬁnal working concentration of 5%. The suspension was
incubated at room temperature for 2 h on a rotary mixer.
Non-solubilized material was removed by centrifugation
at 100,000g for 1 h at 4 C. The supernatant was then
diluted to 2.5% detergent by adding 20 mL of solubiliza-
tion buﬀer to a ﬁnal concentration of 20 mM imidazole
and then applied onto a 1 mL HisTrap HP column (GE
Healthcare) pre-equilibrated with 2.5% detergent plus
20 mM imidazole in solubilization buﬀer. The column
was washed with two column volumes of the same buﬀer
followed by a further three column volumes of 1% b-OG-
containing buﬀer. The hCD81 fractions were eluted with
a linear gradient of 20–500 mM imidazole in solubilization
buﬀer containing 1.0% b-OG. The eluted fractions were
subsequently concentrated and analyzed by SDS–PAGE
and immunoblotting. Electrophoresis was carried out using
an X-CellMini-Cell System (Novex, San Diego, USA) at
200 V for 45 min. Proteins were visualized using Coomassie
Brilliant Blue (0.1% w/v) in an aqueous solution of 40%
methanol (v/v) and 10% glacial acetic acid (v/v) for
60 min and then destained in an aqueous solution of 40%
(v/v) methanol with 10% (v/v) glacial acetic acid.
Protoplast production and analysis
A mid-log phase aliquot of P. pastoris X33-hCD81
cells was resuspended in 50 mM phosphate buﬀer, pH
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were collected by centrifugation at 500g for 3 min and
suspended in 1 mL of the same buﬀer containing 3.7%
paraformaldehyde (PFA) to ﬁx the cells, and incubated
at room temperature for 1 h. The cells were washed twice
with PFA-free buﬀer and once in buﬀer containing 1.2 M
sorbitol (sorbitol buﬀer). Cells were ﬁnally suspended in
0.5 mL sorbitol buﬀer and treated with zymolyase by
adding 50 lL of 10 mg/mL zymolyase-20T and incubat-
ing at 37 C for 1 h. After washing cells once and then
suspending them in sorbitol buﬀer, 6 lL of cells were
added to a 0.1% poly-L-lysine-coated slide and incubated
for 30 min to attach. Slides were gently washed with
phosphate-buﬀered saline (PBS), permeabilized with 1%
Triton X-100 in PBS, blocked and subsequently stained
with primary and ﬂuorochrome-conjugated secondary
antibodies as previously described [15,16]. In addition,
they were incubated in PBS containing 1% bovine serum
albumin (BSA) in the presence or absence of 0.1% sapo-
nin and incubated with anti-hCD81 (M38) or a control
isotype monoclonal antibody on ice for 1 h. Cells were
washed in PBS containing 1% BSA in the presence or
absence of 0.1% saponin and bound antibody detected
by incubating the cells with anti-mouse alexa 488
(R&D Systems) for 1 h, washing to remove unbound
antibody and analyzing by ﬂow cytometry. For the sur-
face staining, the intact protoplasts were stained ﬁrst
and ﬁxed subsequently in 1% PFA before assaying ﬂuo-
rescence by ﬂow cytometry.
Biophysical analyses
A Beckman XLI analytical ultracentrifuge using an 8
cell 50Ti rotor was used for the AUC studies. Samples
of hCD81 were prepared in 20 mM NaPO4, pH 7.4,
250 mM NaCl, 10% glycerol, 100 lM AEBSF (solubiliza-
tion buﬀer) and 1.0% b-OG and were loaded into two
sector cells and centrifuged at 40,000 rpm for 8 h at
4 C. The absorbance of the sample was measured at a
wavelength of 220 nm throughout the cell. A total of
100 measurements were taken throughout each 8 h run.
Data from each experiment were analyzed using the con-
tinuous c(s) distribution model implemented within SED-
FIT94 [17]. Parameters for the partial speciﬁc volume of
the protein, buﬀer viscosity and density were calculated
using SEDNTERP [18].
Circular dichroism spectra were recorded using a JAS-
CO J-810 nitrogen-ﬂushed spectropolarimeter. Samples of
hCD81 were prepared in solubilization buﬀer plus 1.0%
b-OG or DPC. Far-UV CD spectra of samples were col-
lected using cell pathlengths of 0.2 cm in the far-UV
domain and at 25 ± 0.1 C for all experiments, unless
otherwise stated. Spectra were acquired by averaging eight
scans and corrected for buﬀer signal. Data deconvolution
was carried out using CDSSTR [19] using the SMP50 basis
set that contains 37 soluble and 13 membrane protein ref-
erence spectra.Molecular structure analysis
The X-ray crystal structure of the large extracellular
loop (EC2) of hCD81 (PDB ID 1IV5) was analyzed using
Swiss PDB [20]. Secondary structure content was calcu-
lated using the routines within Swiss PDB.
Measurement of HCV E2–hCD81 interaction
Puriﬁed, full-length, recombinant hCD81 together with
bacterially-produced hCD81 EC2 (the positive control;
[21]) and bacteriorhodopsin (the negative control) were
allowed to bind to microtiter plates (Costar High-bonding
polystyrene, Corning Corp.) overnight at 4 C. Plates were
blocked with 1% BSA and washed with PBS containing
0.1% Tween 20 (blocking buﬀer). To conﬁrm that hCD81
antigens had bound the plate, antigen was detected with
anti-CD81 monoclonal antibody, M38 (1 lg/ml). After a
1 h incubation at 37 C, plates were washed and bound
antibody was visualized with a horseradish peroxidase
(HRP)-conjugated anti-mouse antibody (Caltag Laborato-
ries, Inc.) and tetramethyl benzidene (TMB) substrate.
HCV strain H77 (genotype 1) soluble E2 was generated
in human embryonal kidney cells as previously described
[21] and added to hCD81 and control-antigen-coated
plates, and incubated for 1 h at 37 C. Bound E2 was
detected with rat anti-E2 mAb, 9/27, and realized with
HRP-conjugated anti-rat antibody (Caltag Laboratories,
Inc.) and TMB substrate.
Results
hCD81 can be produced in P. pastoris
The entire hCD81 coding sequence was tagged at the 3 0
end with a six histidine tag coding sequence and cloned into
the P. pastoris expression vector pPICZB downstream of
the alcohol oxidase 1 (AOX1) promoter. In order to pre-
vent aggregation and thus to obtain homogeneous recom-
binant protein from P. pastoris, the palmitoylation sites
were eliminated by conservative point mutations to give
the sequence shown in Fig. 1. It has previously been shown
that the removal of palmitoylation sites in various tetraspa-
nins does not aﬀect their overall conformation (unpub-
lished data and [15]). Successful transformants were
identiﬁed through small-scale (3 mL) expression screens.
The highest levels of hCD81 expression were observed at
54 h post-induction in the wild-type X33 strain of P. pasto-
ris (transformant X33-hCD81) in comparison to the GS115
strain (data not shown).
In order to generate large amounts of biomass for sub-
sequent protein puriﬁcation, biophysical and biochemical
studies, ﬂask cultivations (2 L) of transformant X33-
hCD81 were harvested 54 h post-induction. Cellular local-
ization and structural integrity of hCD81 within the mem-
brane was established by immunoblot staining, yielding a
positive immunoblot signal both in the total cell lysate
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only the non-reduced form of hCD81 (both from a hCD81-
producing cell-line and from our recombinant membranes),
in which the critical disulﬁde bridges of EC2 are intact, is
recognized by the conformationally-speciﬁc antibody. The
protein gels for these immunoblots depicted the expected
ladder of bands (data not shown).
Immunoﬂuorescence studies showed that three anti-
hCD81 monoclonal antibodies (mAb): M38, 5A6 and
1D6 [22–24] bound to hCD81-producing yeast protoplasts,
suggesting that the recombinant protein is intact in the
yeast membrane (Fig. 3A–D). In control experiments we16
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Fig. 2. Immunoblot of hCD81 isolated from P. pastoris membranes
expressing pPICZB-hCD81-His6. hCD81 was identiﬁed using both a
commercial monoclonal anti-His6 antibody (Clontech; left panel) and an
anti-hCD81 monoclonal antibody (right panel). Lane 1: total cell lysate,
lane 2: supernatant following centrifugation at 10,000g for 30 min, lane 3:
supernatant after ultracentrifugation at 100,000g for 90 min, lane 4: total
membrane fraction. Samples were not exposed to any reducing agents.
Positions of molecular mass markers (kDa) are indicated on the right-
hand side of the ﬁgure (A). The conformational speciﬁcity of the anti-
hCD81 monoclonal antibody was conﬁrmed by probing reduced and non-
reduced hCD81 samples. Lane 1: MDA-MB-231 cell-line (non-reduced),
lane 2: MDA-MB-231 cell-line (reduced with 1% b-mercaptoethanol), lane
3: total membrane fraction from P. pastoris membranes expressing
pPICZB-hCD81-His6 (non-reduced), lane 4: total membrane fraction
from P. pastoris membranes expressing pPICZB-hCD81-His6 (reduced
with 1% b-mercaptoethanol). Positions of molecular mass markers (kDa)
are indicated on the right-hand side of the ﬁgure (B).detected no staining with anti-hCD81 mAbs in non-
expressing P. pastoris X33 cells and thus observed only a
black panel (data not shown). Furthermore, the mAb
against tetraspanin hCD82 did not stain hCD81-expressing
yeast protoplasts (data not shown). This conﬁrmed the
speciﬁcity of the anti-hCD81 antibody staining. Flow cyto-
metric studies further showed that approximately 80% of
the protoplasts had produced hCD81 and that this did
not increase signiﬁcantly after permeabilizing with saponin
(Fig. 3E). This staining was speciﬁc as M38 failed to bind
to X33 protoplasts and isotype-controlled mAb failed to
bind to X33-hCD81 cells. We therefore concluded that
our recombinant hCD81 was most likely to be correctly
folded and inserted into the P. pastoris membrane.
Solubility screening and puriﬁcation yields 1.75 mg/L b-OG-
solubilized hCD81
A set of nine detergents and mixed micelles previously
used and optimized for membrane proteins including
PM28A/SoPIP2; 1 (detergent used: b-OG [25]), PagP bar-
rel (CYFOS [26]), SERCA (DPC [27]), Arabidopsis thaliana
leaf membrane proteins (Brij-n [28]) and ﬁve others were
evaluated for eﬀective hCD81 solubilization from P. pasto-
ris membranes. Fig. 4 summarizes the solubilization of full-
length hCD81 with these nine detergents where we exam-
ined the proportion of hCD81 solubilized into the superna-
tant compared with that remaining in the pellet in
accordance with standard procedure [25]. The data show
successful solubilization with eight of the nine detergents
with some yielding soluble monomer (b-OG, DPC/CHS
and LDAO) while others also apparently yielded various
amounts of soluble dimer, as revealed by immunoblotting.
In order to investigate the possibility of dimer forma-
tion, hCD81 solubilized in C8E5 was prepared for analyt-
ical ultracentrifugation. It was clear from this experiment
that dimer formation was an artifact of the analytical
SDS–PAGE of this sample (Fig. 4B), as seen previously
[29]. b-OG and DPC were therefore selected for subsequent
solubilization and puriﬁcation for biophysical and bio-
chemical analysis because of the success reported through-
out the literature with membrane proteins, and their
suitability for downstream structural analysis.
Full-length hCD81 containing a carboxy-terminal His-
tag and solubilized in b-OG was puriﬁed to near electropho-
retic homogeneity by nickel-NTA agarose aﬃnity chroma-
tography. The protein eluted as a species with a molecular
mass in the expected region of 26.6 kDa, at a yield of
1.75 mg/L (Fig. 5). Its identity was conﬁrmed by mass spec-
trometry (data not shown). The highermolecularweight spe-
cies seen in lanes 6 and 7 are most probably residual alcohol
oxidase 1, as we have identiﬁed this host protein by mass
spectrometry when producing other recombinant proteins
in P. pastoris. The lower molecular weight form is likely to
be due to residual imidazole or detergent present in the sam-
ple: the structural integrity under non-reducing conditions
was conﬁrmed by Western blotting with anti-hCD81 mAbs
1 10 100 1000 10000
FL1-H
0
20
40
60
80
100
%
 o
f M
ax
1 10 100 1000 10000
FL1-H
0
20
40
60
80
100
%
 o
f M
ax
1 10 100 1000 10000
FL1-H
0
20
40
60
80
100
%
 o
f M
ax
1 10 100 1000 10000
FL1-H
0
20
40
60
80
100
%
 o
f M
ax
E
CD81
X33 X33-hCD81 
SURFACE 
TOTAL
Fig. 3. hCD81 produced in P. pastoris is recognized by monoclonal antibodies to the native protein. P. pastoris strains X33 and X33-hCD81 were ﬁxed in
paraformaldehyde and protoplasts were produced by zymolyase treatment. PermeabilizedX33-hCD81 protoplasts (in TritonX-100) were stainedwithmAbs
to hCD81: M38 (B), 1D6 (C) and mAb 5A6 (D). Staining was visualized with goat anti-mouse IgG Ab conjugated to alexa 488. Panel A shows a phase-
contrast image of protoplasts shown in panel B. Note, that only one of the two protoplasts is stained with anti-hCD81 mAb. This may be due to intrinsic
heterogeneity of the culture of P. pastoris expressing hCD81. The scale bar represents 10 lM. Panel E shows intact or saponin-permeabilized protoplasts
which were incubated with anti-hCD81 mAb M38 (open histogram) and an isotype-matched control irrelevant IgG (grey histogram) for 1 h on ice. Bound
mAb was visualized with anti-mouse Ig alexa 488 and analyzed by ﬂow cytometry. Histograms represent the staining intensity of the bound antibodies.
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protein (Fig. 2). Indeed, antibody binding in protoplasts,crude membrane fractions and puriﬁed hCD81 indicated
the protein is intact throughout the puriﬁcation protocol.
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Fig. 4. Solubility screen of hCD81 extracted from P. pastoris membranes. Both the micelle-bound solubilized proteins in the supernatant (S) and the non-
solubilized proteins in the membrane pellet (P) were detected with an anti-hCD81 monoclonal antibody. Lane 1: n-dodecylphosphocholine (DPC), lane 2:
cyclofos-4 (CYFOS-4), lane 3: n-dodecyl-b-D-maltopyranoside (DDM), lane 4: foscholineiso9 (FCI09), lane 5: lauryldimethylamine oxide (LDAO), lane 6:
pentaethyleneglycol-n-octyl ether (C8E5), lane 7: nDPC-cholesterolhemisuccinate (DPC/CHS), lane 8: docosaethyleneglycolmonohexadecylether (Brij 58),
lane 9: n-octyl-b-D-glucopyranoside (b-OG) (A). Repeat solubilization with C8E5. Both the micelle-bound solubilized proteins in the supernatant (S) and
the non-solubilized proteins in the pellet (P) are shown (B). Samples were not exposed to any reducing agents. Molecular weights are in kDa.
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Fig. 5. Coomassie-stained SDS–polyacrylamide gel showing the puriﬁca-
tion of recombinant hCD81 from P. pastoris membranes. Lane M:
Marker, lane 1: wash 1 with buﬀer containing 2.5% b-OG, lane 2: wash 2
with buﬀer containing 2.5% b-OG, lanes 3–12: eluted fractions of hCD81
from the nickel aﬃnity chromatography column using a linear imidazole
gradient and buﬀer containing 1.0% b-OG. The arrow denotes hCD81. All
samples were run in sample buﬀer containing b-mercaptoethanol.
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hCD81 is a single species in detergent solution
AUC data for b-OG-solubilized hCD81 revealed a sin-
gle peak corresponding to 0.48 S and an absence of aggre-
gated material, as shown in Fig. 6A. These data from AUC
support the observation that dimeric species observed by
SDS–PAGE may well be an artifact caused by the condi-
tions used during the separation: no reducing agent was
included in the loading buﬀer in order to maintain the con-formation of the disulﬁde-bonded extracellular loop, EC2
(Figs. 2 and 4). The dimeric species do not appear on
repeating the SDS–PAGE (Fig. 4B), and indeed have been
similarly identiﬁed by others [29]. The peak observed by
AUC is at a lower value compared with that expected for
a 26.6 kDa protein. Transformation of the data to gain
an estimate of mass leads to a predicted mass for the pro-
tein of 11.7 kDa. This anomalous behavior is likely to be a
result of the interaction of b-OG with the protein. In Figs.
2, 4 and 5, the monomer also runs with a consistent, but
somewhat lower molecular weight than 26.6 kDa (approx-
imately 20 kDa in each case), which is not unexpected for
membrane proteins [30].
Circular dichroism indicates that recombinant hCD81 is
predominantly a-helical in detergent solution
Measurement of circular dichroism spectra of DPC- and
b-OG-solubilized hCD81 produced data consistent with a
protein with a substantial a-helical component (Fig. 6B).
These data were further deconvoluted by CDSSTR in
order to produce a measure of secondary structure content
for the protein (Fig. 6B), conﬁrming the high a-helix con-
tent (77.1%, with a nRMSD for the ﬁt of 0.091). This ﬁgure
compares well with the a-helix content calculated from the
known structural elements of hCD81. hCD81 contains four
predicted transmembrane helices containing a total of 140
amino acids in an a-helical conformation, together with
83 amino acids in a-helices seen in the EC2 X-ray crystal
structure [3]. This equates to a predicted helical content
of 75.2% which is very close to that obtained from the
CD analysis.
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Fig. 6. Analytical ultracentrifugation and CD data for hCD81 in b-OG
micelles collected on a Proteome Lab XL-I instrument. Shown are the
mass distributions of particles within the samples (A). Far-UV CD
spectrum of DPC-solubilized hCD81 were recorded using a JASCO J-810
nitrogen-ﬂushed spectropolarimeter. CD spectra were collected using a
0.2 cm path length cuvette and averaged over 8 scans in the far-UV
domain. Spectra acquired were corrected for the buﬀer signal (B).
0
0.5
1
1.5
2
2.5
3
3.5
0.01 0.02 0.03 0.06 0.13 0.25
Protein concentration (μg/ml)
Buffer only
hCD81 EC2
hCD81
bacteriorhodopsin
0
0.5
1
1.5
2
2.5
3
3.5
4
0.002 0.003 0.006 0.013 0.025
HCV E2 (reciprocal dilution)
O
D
45
0
O
D
45
0
hCD81 EC2
hCD81
bacteriorhodopsin
Fig. 7. Pichia pastoris-produced CD81 binds Hepatitis C virus E2.
Increasing concentrations of hCD81, bacteriorhodopsin and bacterially-
produced hCD81 EC2 were bound to an ELISA plate and tested for
reactivity with a saturating concentration of anti-CD81 M38. Data are
expressed as optical density at 450 nm (A). A saturating concentration of
P. pastoris hCD81, control bacteriorhodopsin protein and hCD81 EC2
were bound to an ELISA plate and tested for their ability to bind
increasing amounts of soluble HCV E2. Bound E2 was realized with an
anti-E2 mAb, 9/27 and anti-rat Ig-HRP. Data are expressed as optical
density at 450 nm (B).
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To investigate whether b-OG-solubilized hCD81 was
able to interact with HCV E2 glycoprotein we established
an ELISA to monitor interactions with a truncated form
of E2 [21]. Increasing concentrations of hCD81 and a bac-
terially-produced form of CD81-EC2 [21] were allowed to
bind to ELISA plates and their adsorption conﬁrmed by
following their reactivity with a saturating concentration
of anti-hCD81 M38 (Fig. 7A). Full-length and truncated
hCD81 bound M38 with similar proﬁles, conﬁrming the
antigenicity of the bound hCD81 antigen(s). Fig. 7B shows
that HCV E2 bound full-length and CD81-EC2 with com-
parable eﬃciency.Discussion
We have demonstrated the ﬁrst over-production of full-
length, human CD81 at a yield of 1.75 mg/L of P. pastorisculture (Fig. 5). This yeast species allows ease of cultiva-
tion, optimization of production and access to the full com-
plement of higher eukaryote-like post-translational
modiﬁcations. This is in contrast to the widely-used pro-
karyotic microbe, Escherichia coli, in which accumulation
of the recombinant protein in inclusion bodies requires
refolding and can lead to much lower levels of fully-func-
tional recombinant protein. To date several other recombi-
nant mammalian membrane proteins have been produced
in P. pastoris for example, mouse 5-hydroxytryptamine
receptor (5HT5A) [31], human b2-adrenergic receptor [31],
and bovine opsin [32]. Moreover, three of the ﬁve recombi-
nant eukaryotic membrane proteins for which there are
high-resolution structures in the protein data bank have
been produced in P. pastoris [25,33,34].
In order to characterize puriﬁed hCD81, we used anti-
hCD81 monoclonal antibodies that recognize epitopes
within EC2 (Fig. 1). Recognition by these conformational-
ly-speciﬁc antibodies suggested that the protein is correctly
folded and allowed us to assess protein conformation by
immunoblot and immunoﬂuorescence from production
through to puriﬁcation. Immunoblotting revealed the
integration of the native protein into the membrane of
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by results of the immunoﬂuorescence and ﬂow cytometric
studies (Fig. 3) which revealed the majority of the protein
located at the cell surface with little or no intracellular
localization. The patchy distribution across the cell surface
is reminiscent of other membrane proteins produced in
yeast [35,36], and may be a result of diﬀerential segregation
into diﬀerent lipid raft domains due to changes in mem-
brane potential, sterol composition and cell physiology
[35,36].
Solubilization screening of hCD81 with nine diﬀerent
detergents, ranging from nonionic to zwitterionic mole-
cules indicated solubilization in eight of the nine
(Fig. 4). It was clear that the nonionic detergents such
as n-octyl-b-D-glucopyranoside (b-OG), n-dodecylphosph-
ocholine in the presence of cholesterol (DPC/CHS), and
lauryldimethylamine oxide (LDAO) were far more suc-
cessful in yielding soluble monomeric hCD81 than the
zwitterionic cyclofos-4 (CYFOS-4) and foscholineiso9
(FCI09). Initial indications of dimeric species were shown
to be artifacts of SDS–PAGE upon repeating the analysis
(Fig. 4B). This phenomenon has also been observed for
other tetraspanin-like proteins [29], and was due in part
to the fact that no reducing agent was included in the
loading buﬀer to maintain the conformation of the disul-
ﬁde-bonded extracellular loop, EC2, in Figs. 2 and 4—
note that reducing agent was present in the buﬀer used
to prepare samples for Fig. 5. Based on these ﬁndings
and other studies in the literature [25,27,37,38], b-OG
and DPC were selected for solubilization scale-up and
downstream processing of hCD81. Biophysical character-
ization of hCD81 in detergent solution employing AUC
conﬁrmed the presence of a single molecular weight spe-
cies. Far-ultraviolet circular dichroism measurements pro-
duced a spectrum which predicts a high a-helical
secondary structure that concurs well with that expected
for hCD81. This puriﬁed protein was shown to bind
HCV E2, suggesting that the protein adopts a conforma-
tion akin to the cell-surface-expressed molecule (Fig. 7).
To date no crystallographic analysis of full-length
hCD81 has been performed due to the diﬃculties in obtain-
ing suﬃcient amounts of stable, active, monomeric protein;
a problem that besets the membrane protein ﬁeld as a
whole. However, an X-ray crystal structure of the soluble
EC2 domain of hCD81 revealed ﬁve helices [3], for which
loop structures were not clearly deﬁned. The adjacent
EC1 domain was absent [39], as was information on bind-
ing to any ligands or lipids. Moreover there are diﬀerences
between the predicted three-dimensional model of the full-
length hCD81 [40] and the EC2 structure [3]. The func-
tional relevance of this soluble, 91 residue disulﬁde-bonded
polypeptide structure is thus debatable, as is the dimer
interface proposed from contacts seen in the crystal lattice.
There is also signiﬁcant evolutionary divergence in the pro-
tein sequences of ligand binding soluble domains among
tetraspanins, thereby making extrapolation to other family
members diﬃcult.The recent 6 A˚ cryo-EM structure of a naturally-
occurring uroplakin tetraspanin 2D array (or ‘‘urothelial
plaque’’) revealed a rod-shaped structural morphology
consisting of 4 TM helical bundles bound to a single
TM helix partner [41]. However, diﬀerences between
the proposed dimer and EC1–EC2 contacts with pre-
dicted models of CD81 [40], CD82 [42], and CD9 [43]
exist and structural information is lacking about the crit-
ical intracellular carboxy-terminal domain which plays
key roles in interaction with a variety of eﬀector proteins
[2,42]. Moreover the uroplakin tetraspanins are atypical
members of the superfamily on account of their natural
assembly into hexagonally-packed 2D crystals and their
highly-speciﬁc interactions with a limited number of part-
ner ligands. Together, this lack of structural information
emphasizes the need for further structural and functional
analysis of intact hCD81, itself a more typical tetra-
spanin with involvement in several key cellular processes.
Questions include the role and positioning of EC1, the
structure–activity relationships of the transmembrane
domains in interactions with partner proteins and other
tetraspanins, and speciﬁcally details of the mechanism
of hCD81 signaling. Crucially, structural data on
hCD81 will greatly facilitate site-directed mutagenesis
studies to deﬁne individual amino acids that are critical
for the interaction of the full-length molecule with
HCV glycoproteins. Recent studies suggest important dif-
ferences in the interaction of HCV with full-length, cell-
expressed forms of hCD81 and recombinant forms com-
prising truncated CD81: some amino acid mutations
exert a phenotype in the context of EC2 but not in the
full length molecule [21]. Hence, analysis of interactions
between full-length hCD81 and viral glycoproteins are
required to investigate the critical amino acids deﬁning
this interaction [44].
To this end, we have produced full-length, recombinant
hCD81 in a highly-pure, homogeneous, active form that is
recognized by conformationally-speciﬁc antibodies, and
which is predominantly a-helical in nature. This study rep-
resents the ﬁrst biophysical characterization of a full-length
recombinant tetraspanin, and opens the way for structure–
activity analyses of this ubiquitous and important family of
transmembrane proteins.
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